Triacetin and a Mushroom Blend Restore Butyrate Production by IBS Microbiomes Ex Vivo, Thus Promoting Barrier Integrity.

Pieter Van den Abbeele, Jonas Poppe, Aurélien Baudot, Lam Dai Vu

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Impact of Triacetin- and Tributyrin-Based Formulations on IBS Microbiome Composition and SCFA Profiles: A Preclinical Study.International journal of molecular sciences · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pieter Van den AbbeeleCryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.ORCID 0000-0002-1399-6332

Jonas PoppeCryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.

Aurélien BaudotCryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.ORCID 0009-0009-4872-6875

Lam Dai VuCryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder, characterized by abdominal pain, altered bowel habits (diarrhea and/or constipation) and a dysbiosis of the gut microbiome. This dysbiosis is difficult to restore via fiber supplementation, which typically promotes gas production, potentially worsening IBS symptoms. We therefore studied how two novel products, triacetin (TA; REBiome™) and a mushroom blend (MB; Hōlistiq™), modulate the microbiome of IBS subjects (

Indexed as

AgaricalesButyratesGastrointestinal MicrobiomeIrritable Bowel SyndromeAdultCaco-2 CellsDysbiosisFatty Acids, VolatileFemaleFermentationHumansIntestinal MucosaMaleMiddle AgedButyratesFatty Acids, Volatilebarrier integritybutyrateIBSmushroomprebioticSCFASIFRtriacetin

Identifiers

PMID41096656

DOI10.3390/ijms26199388

PMCPMC12524982

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.